6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
below	IN	below	below	below	N	O
and	CC	and	and	and	N	O
also	RB	also	also	also	N	O
elsewhere	RB	elsewhere	elsewhere	elsewher	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Hypocalcemia	NNP	hypocalcemia	hypocalcemia	hypocalcemia	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
Infections	NNS	infections	infection	infect	N	B-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)]	NN	)]	)]	)]	N	O

Dermatologic	NNP	dermatologic	dermatologic	dermatolog	N	B-AdverseReaction
Adverse	NNP	adverse	adverse	advers	N	I-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)]	NN	)]	)]	)]	N	O

Osteonecrosis	NN	osteonecrosis	osteonecrosis	osteonecrosi	Y	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
Jaw	NNP	jaw	jaw	jaw	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O

Atypical	JJ	atypical	atypical	atyp	N	B-AdverseReaction
Subtrochanteric	NNP	subtrochanteric	subtrochanteric	subtrochanter	N	I-AdverseReaction
and	CC	and	and	and	N	O
Diaphyseal	NNP	diaphyseal	diaphyseal	diaphys	N	I-AdverseReaction
Femoral	NNP	femoral	femoral	femor	N	I-AdverseReaction
Fractures	NNP	fractures	fracture	fractur	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	NN	)]	)]	)]	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
postmenopausal	JJ	postmenopausal	postmenopausal	postmenopaus	N	O
osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
are	VBP	are	are	are	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
,	,	,	,	,	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
hypercholesterolemia	NN	hypercholesterolemia	hypercholesterolemia	hypercholesterolemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
cystitis	NN	cystitis	cystitis	cystiti	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O

most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
in	IN	in	in	in	N	O
men	NNS	men	men	men	N	O
with	IN	with	with	with	N	O
osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
are	VBP	are	are	are	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
(	(	(	(	(	N	O
per	IN	per	per	per	N	O
patient	NN	patient	patient	patient	N	O
incidence	NN	incidence	incidence	incid	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
adverse	NN	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBD	reported	reported	report	N	O
with	IN	with	with	with	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
bone	JJ	bone	bone	bone	N	O
loss	NN	loss	loss	loss	N	O
receiving	VBG	receiving	receiving	receiv	N	O
androgen	JJ	androgen	androgen	androgen	N	O
deprivation	NN	deprivation	deprivation	depriv	N	O
therapy	NN	therapy	therapy	therapi	N	O
for	IN	for	for	for	N	O
prostate	NN	prostate	prostate	prostat	N	O
cancer	NN	cancer	cancer	cancer	Y	O
or	CC	or	or	or	N	O
adjuvant	JJ	adjuvant	adjuvant	adjuv	N	O
aromatase	NN	aromatase	aromatase	aromatas	N	O
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	O
therapy	NN	therapy	therapy	therapi	N	O
for	IN	for	for	for	N	O
breast	NN	breast	breast	breast	N	O
cancer	NN	cancer	cancer	cancer	Y	O
are	VBP	are	are	are	N	O
arthralgia	VBN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
.	.	.	.	.	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
and	CC	and	and	and	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
have	VBP	have	have	have	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
postmenopausal	JJ	postmenopausal	postmenopausal	postmenopaus	N	O
osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
are	VBP	are	are	are	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
and	CC	and	and	and	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
Postmarketing	NNP	postmarketing	postmarketing	postmarket	N	O
Active	NNP	active	active	activ	N	O
Safety	NNP	safety	safety	safeti	N	O
Surveillance	NNP	surveillance	surveillance	surveil	N	O
Program	NNP	program	program	program	N	O
is	VBZ	is	is	is	N	O
available	JJ	available	available	avail	N	O
to	TO	to	to	to	N	O
collect	VB	collect	collect	collect	N	O
information	NN	information	information	inform	N	O
from	IN	from	from	from	N	O
prescribers	NNS	prescribers	prescribers	prescrib	N	O
on	IN	on	on	on	N	O
specific	JJ	specific	specific	specif	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
.	.	.	.	.	N	O

Please	NNP	please	please	pleas	N	O
see	VB	see	see	see	N	O
www	NN	www	www	www	N	O
.	.	.	.	.	N	O
proliasafety	NN	proliasafety	proliasafety	proliasafeti	N	O
.	.	.	.	.	N	O
com	NN	com	com	com	N	O
or	CC	or	or	or	N	O
call	VB	call	call	call	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
772	CD	772	772	772	N	O
-	:	-	-	-	N	O
6436	CD	6436	6436	6436	N	O
for	IN	for	for	for	N	O
more	JJR	more	more	more	N	O
information	NN	information	information	inform	N	O
about	IN	about	about	about	N	O
this	DT	this	this	thi	N	O
program	NN	program	program	program	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Postmenopausal	JJ	postmenopausal	postmenopausal	postmenopaus	N	O
osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
and	CC	and	and	and	N	O
more	JJR	more	more	more	N	O
common	JJ	common	common	common	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
,	,	,	,	,	N	O
hypercholesterolemia	NN	hypercholesterolemia	hypercholesterolemia	hypercholesterolemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
cystitis	NN	cystitis	cystitis	cystiti	Y	B-AdverseReaction
.	.	.	.	.	N	O

Pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

Male	JJ	male	male	male	N	O
Osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
and	CC	and	and	and	N	O
more	JJR	more	more	more	N	O
common	JJ	common	common	common	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

Bone	NNP	bone	bone	bone	N	O
loss	NN	loss	loss	loss	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
hormone	VB	hormone	hormone	hormon	N	O
ablation	NN	ablation	ablation	ablat	N	O
for	IN	for	for	for	N	O
cancer	NN	cancer	cancer	cancer	Y	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
and	CC	and	and	and	N	O
more	JJR	more	more	more	N	O
common	JJ	common	common	common	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
.	.	.	.	.	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
and	CC	and	and	and	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
have	VBP	have	have	have	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Amgen	NNP	amgen	amgen	amgen	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
77	CD	77	77	77	N	O
-	:	-	-	-	N	O
AMGEN	NNP	amgen	amgen	amgen	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
772	CD	772	772	772	N	O
-	:	-	-	-	N	O
6436	CD	6436	6436	6436	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O

Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
Postmenopausal	NNP	postmenopausal	postmenopausal	postmenopaus	N	O
Women	NNP	women	woman	women	N	O
with	IN	with	with	with	N	O
Osteoporosis	NNP	osteoporosis	osteoporosis	osteoporosi	Y	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
postmenopausal	JJ	postmenopausal	postmenopausal	postmenopaus	N	O
osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
was	VBD	was	wa	wa	N	O
assessed	VBN	assessed	assessed	assess	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
year	NN	year	year	year	N	O
,	,	,	,	,	N	O
randomized	VBN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
multinational	JJ	multinational	multinational	multin	N	O
study	NN	study	study	studi	N	O
of	IN	of	of	of	N	O
7808	CD	7808	7808	7808	N	O
postmenopausal	JJ	postmenopausal	postmenopausal	postmenopaus	N	O
women	NNS	women	woman	women	N	O
aged	VBD	aged	aged	age	N	O
60	CD	60	60	60	N	O
to	TO	to	to	to	N	O
91	CD	91	91	91	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
3876	CD	3876	3876	3876	N	O
women	NNS	women	woman	women	N	O
were	VBD	were	were	were	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
3886	CD	3886	3886	3886	N	O
women	NNS	women	woman	women	N	O
were	VBD	were	were	were	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
administered	VBD	administered	administered	administ	N	O
subcutaneously	RB	subcutaneously	subcutaneously	subcutan	N	O
once	RB	once	once	onc	N	O
every	DT	every	every	everi	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
60	CD	60	60	60	N	O
mg	NN	mg	mg	mg	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
women	NNS	women	woman	women	N	O
were	VBD	were	were	were	N	O
instructed	VBN	instructed	instructed	instruct	N	O
to	TO	to	to	to	N	O
take	VB	take	take	take	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1000	CD	1000	1000	1000	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
calcium	NN	calcium	calcium	calcium	Y	O
and	CC	and	and	and	N	O
400	CD	400	400	400	N	O
IU	NNP	iu	iu	iu	N	O
of	IN	of	of	of	N	O
vitamin	NNP	vitamin	vitamin	vitamin	N	O
D	NNP	d	d	d	N	O
supplementation	NN	supplementation	supplementation	supplement	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
all	DT	all	all	all	N	O
-	:	-	-	-	N	O
cause	NN	cause	cause	caus	N	O
mortality	NN	mortality	mortality	mortal	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
2.3%	CD	2.3%	2.3%	2.3%	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
90	CD	90	90	90	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
70	CD	70	70	70	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
nonfatal	JJ	nonfatal	nonfatal	nonfat	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
was	VBD	was	wa	wa	N	O
24.2%	CD	24.2%	24.2%	24.2%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
25.0%	CD	25.0%	25.0%	25.0%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
percentage	NN	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
withdrew	VBP	withdrew	withdrew	withdrew	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
study	NN	study	study	studi	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
was	VBD	was	wa	wa	N	O
2.1%	CD	2.1%	2.1%	2.1%	N	O
and	CC	and	and	and	N	O
2.4%	CD	2.4%	2.4%	2.4%	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
groups	NNS	groups	group	group	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
postmenopausal	JJ	postmenopausal	postmenopausal	postmenopaus	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
and	CC	and	and	and	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
women	NNS	women	woman	women	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
women	NNS	women	woman	women	N	O
are	VBP	are	are	are	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
table	NN	table	table	tabl	N	O
below	IN	below	below	below	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Occurring	NNP	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Osteoporosis	NNP	osteoporosis	osteoporosis	osteoporosi	Y	O
and	CC	and	and	and	N	O
More	RBR	more	more	more	N	O
Frequently	RB	frequently	frequently	frequent	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O

SYSTEM	NNP	system	system	system	N	O
ORGAN	NNP	organ	organ	organ	N	O
CLASS	NNP	class	class	class	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
3886	CD	3886	3886	3886	N	O
)	)	)	)	)	N	O
n	FW	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
3876	CD	3876	3876	3876	N	O
)	)	)	)	)	N	O
n	FW	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

BLOOD	NNP	blood	blood	blood	N	O
AND	NNP	and	and	and	N	O
LYMPHATIC	NNP	lymphatic	lymphatic	lymphat	N	O
SYSTEM	NNP	system	system	system	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O

Anemia	$	anemia	anemia	anemia	Y	B-AdverseReaction
129	CD	129	129	129	N	O
(	(	(	(	(	N	O
3.3	CD	3.3	3.3	3.3	N	O
)	)	)	)	)	N	O
107	CD	107	107	107	N	O
(	(	(	(	(	N	O
2.8	CD	2.8	2.8	2.8	N	O
)	)	)	)	)	N	O

CARDIAC	NNP	cardiac	cardiac	cardiac	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O

Angina	NNP	angina	angina	angina	N	B-AdverseReaction
pectoris	VBZ	pectoris	pectoris	pectori	N	I-AdverseReaction
101	CD	101	101	101	N	O
(	(	(	(	(	N	O
2.6	CD	2.6	2.6	2.6	N	O
)	)	)	)	)	N	O
87	CD	87	87	87	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O

Atrial	JJ	atrial	atrial	atrial	N	B-AdverseReaction
fibrillation	NN	fibrillation	fibrillation	fibril	Y	I-AdverseReaction
79	CD	79	79	79	N	O
(	(	(	(	(	N	O
2.0	CD	2.0	2.0	2.0	N	O
)	)	)	)	)	N	O
77	CD	77	77	77	N	O
(	(	(	(	(	N	O
2.0	CD	2.0	2.0	2.0	N	O
)	)	)	)	)	N	O

EAR	NN	ear	ear	ear	N	O
AND	CC	and	and	and	N	O
LABYRINTH	NNP	labyrinth	labyrinth	labyrinth	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O

Vertigo	NNP	vertigo	vertigo	vertigo	Y	B-AdverseReaction
195	CD	195	195	195	N	O
(	(	(	(	(	N	O
5.0	CD	5.0	5.0	5.0	N	O
)	)	)	)	)	N	O
187	CD	187	187	187	N	O
(	(	(	(	(	N	O
4.8	CD	4.8	4.8	4.8	N	O
)	)	)	)	)	N	O

GASTROINTESTINAL	NNP	gastrointestinal	gastrointestinal	gastrointestin	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
upper	JJ	upper	upper	upper	N	I-AdverseReaction
129	CD	129	129	129	N	O
(	(	(	(	(	N	O
3.3	CD	3.3	3.3	3.3	N	O
)	)	)	)	)	N	O
111	CD	111	111	111	N	O
(	(	(	(	(	N	O
2.9	CD	2.9	2.9	2.9	N	O
)	)	)	)	)	N	O

Flatulence	NN	flatulence	flatulence	flatul	Y	B-AdverseReaction
84	CD	84	84	84	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
53	CD	53	53	53	N	O
(	(	(	(	(	N	O
1.4	CD	1.4	1.4	1.4	N	O
)	)	)	)	)	N	O

Gastroesophageal	NNP	gastroesophageal	gastroesophageal	gastroesophag	N	B-AdverseReaction
reflux	VBZ	reflux	reflux	reflux	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
80	CD	80	80	80	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O
66	CD	66	66	66	N	O
(	(	(	(	(	N	O
1.7	CD	1.7	1.7	1.7	N	O
)	)	)	)	)	N	O

GENERAL	NNP	general	general	gener	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O
AND	NNP	and	and	and	N	O
ADMINISTRATION	NNP	administration	administration	administr	N	O
SITE	NNP	site	site	site	N	O
CONDITIONS	NNP	conditions	condition	condit	N	O

Edema	NNP	edema	edema	edema	Y	B-AdverseReaction
peripheral	JJ	peripheral	peripheral	peripher	N	I-AdverseReaction
189	CD	189	189	189	N	O
(	(	(	(	(	N	O
4.9	CD	4.9	4.9	4.9	N	O
)	)	)	)	)	N	O
155	CD	155	155	155	N	O
(	(	(	(	(	N	O
4.0	CD	4.0	4.0	4.0	N	O
)	)	)	)	)	N	O

Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
90	CD	90	90	90	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
73	CD	73	73	73	N	O
(	(	(	(	(	N	O
1.9	CD	1.9	1.9	1.9	N	O
)	)	)	)	)	N	O

INFECTIONS	NNP	infections	infection	infect	N	O
AND	CC	and	and	and	N	O
INFESTATIONS	NNP	infestations	infestation	infest	N	O

Cystitis	NN	cystitis	cystitis	cystiti	Y	B-AdverseReaction
228	CD	228	228	228	N	O
(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)	)	)	)	)	N	O
225	CD	225	225	225	N	O
(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
190	CD	190	190	190	N	O
(	(	(	(	(	N	O
4.9	CD	4.9	4.9	4.9	N	O
)	)	)	)	)	N	O
167	CD	167	167	167	N	O
(	(	(	(	(	N	O
4.3	CD	4.3	4.3	4.3	N	O
)	)	)	)	)	N	O

Pneumonia	NNP	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
152	CD	152	152	152	N	O
(	(	(	(	(	N	O
3.9	CD	3.9	3.9	3.9	N	O
)	)	)	)	)	N	O
150	CD	150	150	150	N	O
(	(	(	(	(	N	O
3.9	CD	3.9	3.9	3.9	N	O
)	)	)	)	)	N	O

Pharyngitis	NN	pharyngitis	pharyngitis	pharyng	Y	B-AdverseReaction
91	CD	91	91	91	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
78	CD	78	78	78	N	O
(	(	(	(	(	N	O
2.0	CD	2.0	2.0	2.0	N	O
)	)	)	)	)	N	O

Herpes	NNP	herpes	herpes	herp	N	B-AdverseReaction
zoster	NN	zoster	zoster	zoster	N	I-AdverseReaction
79	CD	79	79	79	N	O
(	(	(	(	(	N	O
2.0	CD	2.0	2.0	2.0	N	O
)	)	)	)	)	N	O
72	CD	72	72	72	N	O
(	(	(	(	(	N	O
1.9	CD	1.9	1.9	1.9	N	O
)	)	)	)	)	N	O

METABOLISM	NNP	metabolism	metabolism	metabol	N	O
AND	CC	and	and	and	N	O
NUTRITION	NNP	nutrition	nutrition	nutrit	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O

Hypercholesterolemia	$	hypercholesterolemia	hypercholesterolemia	hypercholesterolemia	Y	B-AdverseReaction
280	CD	280	280	280	N	O
(	(	(	(	(	N	O
7.2	CD	7.2	7.2	7.2	N	O
)	)	)	)	)	N	O
236	CD	236	236	236	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

MUSCULOSKELETAL	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
AND	NNP	and	and	and	N	O
CONNECTIVE	NNP	connective	connective	connect	N	O
TISSUE	NNP	tissue	tissue	tissu	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O

Back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
1347	CD	1347	1347	1347	N	O
(	(	(	(	(	N	O
34.7	CD	34.7	34.7	34.7	N	O
)	)	)	)	)	N	O
1340	CD	1340	1340	1340	N	O
(	(	(	(	(	N	O
34.6	CD	34.6	34.6	34.6	N	O
)	)	)	)	)	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
453	CD	453	453	453	N	O
(	(	(	(	(	N	O
11.7	CD	11.7	11.7	11.7	N	O
)	)	)	)	)	N	O
430	CD	430	430	430	N	O
(	(	(	(	(	N	O
11.1	CD	11.1	11.1	11.1	N	O
)	)	)	)	)	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
297	CD	297	297	297	N	O
(	(	(	(	(	N	O
7.6	CD	7.6	7.6	7.6	N	O
)	)	)	)	)	N	O
291	CD	291	291	291	N	O
(	(	(	(	(	N	O
7.5	CD	7.5	7.5	7.5	N	O
)	)	)	)	)	N	O

Bone	NNP	bone	bone	bone	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
142	CD	142	142	142	N	O
(	(	(	(	(	N	O
3.7	CD	3.7	3.7	3.7	N	O
)	)	)	)	)	N	O
117	CD	117	117	117	N	O
(	(	(	(	(	N	O
3.0	CD	3.0	3.0	3.0	N	O
)	)	)	)	)	N	O

Myalgia	NNP	myalgia	myalgia	myalgia	Y	B-AdverseReaction
114	CD	114	114	114	N	O
(	(	(	(	(	N	O
2.9	CD	2.9	2.9	2.9	N	O
)	)	)	)	)	N	O
94	CD	94	94	94	N	O
(	(	(	(	(	N	O
2.4	CD	2.4	2.4	2.4	N	O
)	)	)	)	)	N	O

Spinal	NNP	spinal	spinal	spinal	N	B-AdverseReaction
osteoarthritis	NN	osteoarthritis	osteoarthritis	osteoarthr	Y	I-AdverseReaction
82	CD	82	82	82	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O
64	CD	64	64	64	N	O
(	(	(	(	(	N	O
1.7	CD	1.7	1.7	1.7	N	O
)	)	)	)	)	N	O

NERVOUS	NNP	nervous	nervous	nervou	Y	O
SYSTEM	NNP	system	system	system	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O

Sciatica	NNP	sciatica	sciatica	sciatica	Y	B-AdverseReaction
178	CD	178	178	178	N	O
(	(	(	(	(	N	O
4.6	CD	4.6	4.6	4.6	N	O
)	)	)	)	)	N	O
149	CD	149	149	149	N	O
(	(	(	(	(	N	O
3.8	CD	3.8	3.8	3.8	N	O
)	)	)	)	)	N	O

PSYCHIATRIC	NN	psychiatric	psychiatric	psychiatr	N	O
DISORDERS	NNS	disorders	disorder	disord	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
126	CD	126	126	126	N	O
(	(	(	(	(	N	O
3.2	CD	3.2	3.2	3.2	N	O
)	)	)	)	)	N	O
122	CD	122	122	122	N	O
(	(	(	(	(	N	O
3.1	CD	3.1	3.1	3.1	N	O
)	)	)	)	)	N	O

SKIN	NNP	skin	skin	skin	N	O
AND	NNP	and	and	and	N	O
SUBCUTANEOUS	NNP	subcutaneous	subcutaneous	subcutan	N	O
TISSUE	NNP	tissue	tissue	tissu	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
96	CD	96	96	96	N	O
(	(	(	(	(	N	O
2.5	CD	2.5	2.5	2.5	N	O
)	)	)	)	)	N	O
79	CD	79	79	79	N	O
(	(	(	(	(	N	O
2.0	CD	2.0	2.0	2.0	N	O
)	)	)	)	)	N	O

Pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
87	CD	87	87	87	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
82	CD	82	82	82	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O

Hypocalcemia	NNP	hypocalcemia	hypocalcemia	hypocalcemia	Y	B-AdverseReaction
Decreases	VBZ	decreases	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
calcium	NN	calcium	calcium	calcium	Y	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
to	TO	to	to	to	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
8.5	CD	8.5	8.5	8.5	N	O
mg	JJ	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
at	IN	at	at	at	N	O
any	DT	any	any	ani	N	O
visit	NN	visit	visit	visit	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
women	NNS	women	woman	women	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
1.7%	CD	1.7%	1.7%	1.7%	N	O
women	NNS	women	woman	women	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
nadir	NN	nadir	nadir	nadir	N	O
in	IN	in	in	in	N	O
serum	JJ	serum	serum	serum	N	O
calcium	NN	calcium	calcium	calcium	Y	O
level	NN	level	level	level	N	O
occurs	VBZ	occurs	occurs	occur	N	O
at	IN	at	at	at	N	O
approximately	RB	approximately	approximately	approxim	N	O
day	NN	day	day	day	N	O
10	CD	10	10	10	N	O
after	IN	after	after	after	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
dosing	VBG	dosing	dosing	dose	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
normal	JJ	normal	normal	normal	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O

clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
impaired	JJ	impaired	impaired	impair	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
likely	JJ	likely	likely	like	N	O
to	TO	to	to	to	N	O
have	VB	have	have	have	N	O
greater	JJR	greater	greater	greater	N	O
reductions	NNS	reductions	reduction	reduct	N	O
in	IN	in	in	in	N	O
serum	JJ	serum	serum	serum	N	O
calcium	NN	calcium	calcium	calcium	Y	O
levels	NNS	levels	level	level	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
normal	JJ	normal	normal	normal	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
study	NN	study	study	studi	N	O
of	IN	of	of	of	N	O
55	CD	55	55	55	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
varying	VBG	varying	varying	vari	N	O
degrees	NNS	degrees	degree	degre	N	O
of	IN	of	of	of	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
,	,	,	,	,	N	O
serum	JJ	serum	serum	serum	N	O
calcium	NN	calcium	calcium	calcium	Y	O
levels	NNS	levels	level	level	N	O
7.5	CD	7.5	7.5	7.5	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
or	CC	or	or	or	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	B-AdverseReaction
hypocalcemia	NN	hypocalcemia	hypocalcemia	hypocalcemia	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
5	CD	5	5	5	N	O
subjects	NNS	subjects	subject	subject	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
included	VBD	included	included	includ	N	O
no	DT	no	no	no	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
normal	JJ	normal	normal	normal	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
group	NN	group	group	group	N	O
,	,	,	,	,	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
creatinine	JJ	creatinine	creatinine	creatinin	Y	O
clearance	NN	clearance	clearance	clearanc	N	O
50	CD	50	50	50	N	O
to	TO	to	to	to	N	O
80	CD	80	80	80	N	O
mL	NNS	ml	ml	ml	N	O
min	JJ	min	min	min	N	O
group	NN	group	group	group	N	O
,	,	,	,	,	N	O
29%	CD	29%	29%	29%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
creatinine	JJ	creatinine	creatinine	creatinin	Y	O
clearance	NN	clearance	clearance	clearanc	N	O
30	CD	30	30	30	N	O
mL	NN	ml	ml	ml	N	O
min	NN	min	min	min	N	O
group	NN	group	group	group	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
29%	CD	29%	29%	29%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
hemodialysis	NN	hemodialysis	hemodialysis	hemodialysi	Y	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
subjects	NNS	subjects	subject	subject	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
receive	VB	receive	receive	receiv	N	O
calcium	NN	calcium	calcium	calcium	Y	O
and	CC	and	and	and	N	O
vitamin	NN	vitamin	vitamin	vitamin	N	O
D	NNP	d	d	d	N	O
supplementation	NN	supplementation	supplementation	supplement	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
study	NN	study	study	studi	N	O
of	IN	of	of	of	N	O
4550	CD	4550	4550	4550	N	O
postmenopausal	JJ	postmenopausal	postmenopausal	postmenopaus	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
change	NN	change	change	chang	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
in	IN	in	in	in	N	O
serum	JJ	serum	serum	serum	N	O
calcium	NN	calcium	calcium	calcium	Y	O
level	NN	level	level	level	N	O
10	CD	10	10	10	N	O
days	NNS	days	day	day	N	O
after	IN	after	after	after	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
dosing	NN	dosing	dosing	dose	N	O
was	VBD	was	wa	wa	N	O
-	:	-	-	-	N	O
5.5%	CD	5.5%	5.5%	5.5%	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
creatinine	JJ	creatinine	creatinine	creatinin	Y	O
clearance	NN	clearance	clearance	clearanc	N	O
30	CD	30	30	30	N	O
mL	NN	ml	ml	ml	N	O
min	NN	min	min	min	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

-	:	-	-	-	N	O
3.1%	CD	3.1%	3.1%	3.1%	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
creatinine	JJ	creatinine	creatinine	creatinin	Y	O
clearance	NN	clearance	clearance	clearanc	N	O
30	CD	30	30	30	N	O
mL	NN	ml	ml	ml	N	O
min	NN	min	min	min	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
Infections	NNP	infections	infection	infect	N	O
Receptor	NNP	receptor	receptor	receptor	N	O
activator	NN	activator	activator	activ	N	O
of	IN	of	of	of	N	O
nuclear	JJ	nuclear	nuclear	nuclear	N	O
factor	NN	factor	factor	factor	N	O
kappa	SYM	kappa	kappa	kappa	N	O
-	:	-	-	-	N	O
B	NN	b	b	b	N	O
ligand	NN	ligand	ligand	ligand	N	O
(	(	(	(	(	N	O
RANKL	NNP	rankl	rankl	rankl	N	O
)	)	)	)	)	N	O
is	VBZ	is	is	is	N	O
expressed	VBN	expressed	expressed	express	N	O
on	IN	on	on	on	N	O
activated	JJ	activated	activated	activ	N	O
T	NNP	t	t	t	N	O
and	CC	and	and	and	N	O
B	NNP	b	b	b	N	O
lymphocytes	NNS	lymphocytes	lymphocyte	lymphocyt	Y	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
lymph	JJ	lymph	lymph	lymph	N	O
nodes	NNS	nodes	node	node	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
RANKL	NNP	rankl	rankl	rankl	N	O
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	B-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
study	NN	study	study	studi	N	O
of	IN	of	of	of	N	O
7808	CD	7808	7808	7808	N	O
postmenopausal	JJ	postmenopausal	postmenopausal	postmenopaus	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
death	NN	death	death	death	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
in	IN	in	in	in	N	O
both	DT	both	both	both	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
treatment	NN	treatment	treatment	treatment	N	O
groups	NNS	groups	group	group	N	O
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
nonfatal	JJ	nonfatal	nonfatal	nonfat	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
3.3%	CD	3.3%	3.3%	3.3%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
4.0%	CD	4.0%	4.0%	4.0%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
groups	NNS	groups	group	group	N	O
.	.	.	.	.	N	O

Hospitalizations	NNS	hospitalizations	hospitalization	hospit	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
abdomen	NNS	abdomen	abdomen	abdomen	N	I-AdverseReaction
(	(	(	(	(	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
placebo	NN	placebo	placebo	placebo	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

0.9%	CD	0.9%	0.9%	0.9%	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
(	(	(	(	(	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
placebo	NN	placebo	placebo	placebo	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

0.7%	CD	0.7%	0.7%	0.7%	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
ear	NN	ear	ear	ear	N	I-AdverseReaction
(	(	(	(	(	N	O
0.0%	CD	0.0%	0.0%	0.0%	N	O
placebo	NN	placebo	placebo	placebo	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

0.1%	CD	0.1%	0.1%	0.1%	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

Endocarditis	NN	endocarditis	endocarditis	endocard	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
no	DT	no	no	no	N	O
placebo	NN	placebo	placebo	placebo	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
.	.	.	.	.	N	O

Skin	NNP	skin	skin	skin	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
erysipelas	NNS	erysipelas	erysipelas	erysipela	Y	B-AdverseReaction
and	CC	and	and	and	N	O
cellulitis	NN	cellulitis	cellulitis	cellul	Y	B-AdverseReaction
,	,	,	,	,	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
(	(	(	(	(	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
placebo	NN	placebo	placebo	placebo	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

0.4%	CD	0.4%	0.4%	0.4%	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
that	DT	that	that	that	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Dermatologic	NNP	dermatologic	dermatologic	dermatolog	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
A	NNP	a	a	a	N	O
significantly	RB	significantly	significantly	significantli	N	O
higher	JJR	higher	higher	higher	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
developed	VBD	developed	developed	develop	N	O
epidermal	JJ	epidermal	epidermal	epiderm	N	B-AdverseReaction
and	CC	and	and	and	N	O
dermal	JJ	dermal	dermal	dermal	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
(	(	(	(	(	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
dermatitis	NN	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
,	,	,	,	,	N	O
eczema	NN	eczema	eczema	eczema	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
rashes	NNS	rashes	rash	rash	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
8.2%	CD	8.2%	8.2%	8.2%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
10.8%	CD	10.8%	10.8%	10.8%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
groups	NNS	groups	group	group	N	O
(	(	(	(	(	N	O
p	VB	p	p	p	Y	O
0.0001	CD	0.0001	0.0001	0.0001	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Most	JJS	most	most	most	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	O
specific	JJ	specific	specific	specif	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
injection	NN	injection	injection	inject	Y	O
site	NN	site	site	site	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Osteonecrosis	NN	osteonecrosis	osteonecrosis	osteonecrosi	Y	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
Jaw	NNP	jaw	jaw	jaw	N	I-AdverseReaction
ONJ	NNP	onj	onj	onj	N	B-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
program	NN	program	program	program	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Atypical	JJ	atypical	atypical	atyp	N	O
Subtrochanteric	NNP	subtrochanteric	subtrochanteric	subtrochanter	N	O
and	CC	and	and	and	N	O
Diaphyseal	NNP	diaphyseal	diaphyseal	diaphys	N	O
Fractures	NNP	fractures	fracture	fractur	N	O
In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
program	NN	program	program	program	N	O
,	,	,	,	,	N	O
atypical	JJ	atypical	atypical	atyp	N	B-AdverseReaction
femoral	JJ	femoral	femoral	femor	N	I-AdverseReaction
fractures	NNS	fractures	fracture	fractur	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
time	NN	time	time	time	N	O
of	IN	of	of	of	N	O
atypical	JJ	atypical	atypical	atyp	N	B-AdverseReaction
femoral	JJ	femoral	femoral	femor	N	I-AdverseReaction
fracture	NN	fracture	fracture	fractur	Y	I-AdverseReaction
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
was	VBD	was	wa	wa	N	O
as	RB	as	a	as	N	O
early	JJ	early	early	earli	N	O
as	IN	as	a	as	N	O
21	CD	21	21	21	N	O
2	CD	2	2	2	N	O
years	NNS	years	year	year	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Pancreatitis	NNP	pancreatitis	pancreatitis	pancreat	Y	O
Pancreatitis	NNP	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
4	CD	4	4	4	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
8	CD	8	8	8	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
groups	NNS	groups	group	group	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
reports	NNS	reports	report	report	N	O
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
patient	NN	patient	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
all	DT	all	all	all	N	O
8	CD	8	8	8	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
group	NN	group	group	group	N	O
had	VBD	had	had	had	N	O
serious	JJ	serious	serious	seriou	N	O
events	NNS	events	event	event	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
one	CD	one	one	one	N	O
death	NN	death	death	death	Y	B-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

Several	JJ	several	several	sever	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
prior	JJ	prior	prior	prior	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
time	NN	time	time	time	N	O
from	IN	from	from	from	N	O
product	NN	product	product	product	N	O
administration	NN	administration	administration	administr	N	O
to	TO	to	to	to	N	O
event	NN	event	event	event	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
was	VBD	was	wa	wa	N	O
variable	JJ	variable	variable	variabl	N	O
.	.	.	.	.	N	O

New	NNP	new	new	new	N	O
Malignancies	NNP	malignancies	malignancy	malign	N	O
The	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
new	JJ	new	new	new	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
4.3%	CD	4.3%	4.3%	4.3%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
4.8%	CD	4.8%	4.8%	4.8%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
groups	NNS	groups	group	group	N	O
.	.	.	.	.	N	O

New	NNP	new	new	new	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
breast	NN	breast	breast	breast	N	I-AdverseReaction
(	(	(	(	(	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
placebo	NN	placebo	placebo	placebo	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

0.9%	CD	0.9%	0.9%	0.9%	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
reproductive	JJ	reproductive	reproductive	reproduct	N	I-AdverseReaction
system	NN	system	system	system	N	I-AdverseReaction
(	(	(	(	(	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
placebo	NN	placebo	placebo	placebo	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

0.5%	CD	0.5%	0.5%	0.5%	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	I-AdverseReaction
system	NN	system	system	system	N	I-AdverseReaction
(	(	(	(	(	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
placebo	NN	placebo	placebo	placebo	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

0.9%	CD	0.9%	0.9%	0.9%	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
established	VBN	established	established	establish	N	O
.	.	.	.	.	N	O

Treatment	NN	treatment	treatment	treatment	N	O
to	TO	to	to	to	N	O
Increase	NNP	increase	increase	increas	N	O
Bone	NNP	bone	bone	bone	N	O
Mass	NNP	mass	mass	mass	Y	O
in	IN	in	in	in	N	O
Men	NNP	men	men	men	N	O
with	IN	with	with	with	N	O
Osteoporosis	NNP	osteoporosis	osteoporosis	osteoporosi	Y	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
men	NNS	men	men	men	N	O
with	IN	with	with	with	N	O
osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
was	VBD	was	wa	wa	N	O
assessed	VBN	assessed	assessed	assess	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
year	NN	year	year	year	N	O
randomized	VBN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
study	NN	study	study	studi	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
120	CD	120	120	120	N	O
men	NNS	men	men	men	N	O
were	VBD	were	were	were	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
120	CD	120	120	120	N	O
men	NNS	men	men	men	N	O
were	VBD	were	were	were	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
administered	VBD	administered	administered	administ	N	O
subcutaneously	RB	subcutaneously	subcutaneously	subcutan	N	O
once	RB	once	once	onc	N	O
every	DT	every	every	everi	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
60	CD	60	60	60	N	O
mg	NN	mg	mg	mg	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
men	NNS	men	men	men	N	O
were	VBD	were	were	were	N	O
instructed	VBN	instructed	instructed	instruct	N	O
to	TO	to	to	to	N	O
take	VB	take	take	take	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1000	CD	1000	1000	1000	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
calcium	NN	calcium	calcium	calcium	Y	O
and	CC	and	and	and	N	O
800	CD	800	800	800	N	O
IU	NNP	iu	iu	iu	N	O
of	IN	of	of	of	N	O
vitamin	NNP	vitamin	vitamin	vitamin	N	O
D	NNP	d	d	d	N	O
supplementation	NN	supplementation	supplementation	supplement	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
all	DT	all	all	all	N	O
-	:	-	-	-	N	O
cause	NN	cause	cause	caus	N	O
mortality	NN	mortality	mortality	mortal	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
nonfatal	JJ	nonfatal	nonfatal	nonfat	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
was	VBD	was	wa	wa	N	O
7.5%	CD	7.5%	7.5%	7.5%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
8.3%	CD	8.3%	8.3%	8.3%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
percentage	NN	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
withdrew	VBP	withdrew	withdrew	withdrew	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
study	NN	study	study	studi	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
was	VBD	was	wa	wa	N	O
0%	CD	0%	0%	0%	N	O
and	CC	and	and	and	N	O
2.5%	CD	2.5%	2.5%	2.5%	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
groups	NNS	groups	group	group	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
men	NNS	men	men	men	N	O
with	IN	with	with	with	N	O
osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
and	CC	and	and	and	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
with	IN	with	with	with	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
(	(	(	(	(	N	O
6.7%	CD	6.7%	6.7%	6.7%	N	O
placebo	NN	placebo	placebo	placebo	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

8.3%	CD	8.3%	8.3%	8.3%	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
arthralgia	RB	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
(	(	(	(	(	N	O
5.8%	CD	5.8%	5.8%	5.8%	N	O
placebo	NN	placebo	placebo	placebo	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

6.7%	CD	6.7%	6.7%	6.7%	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
(	(	(	(	(	N	O
5.8%	CD	5.8%	5.8%	5.8%	N	O
placebo	NN	placebo	placebo	placebo	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

6.7%	CD	6.7%	6.7%	6.7%	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
Infections	NNP	infections	infection	infect	N	O
S	NNP	s	s	s	N	B-Severity
erious	JJ	erious	erious	eriou	N	I-Severity
infection	NN	infection	infection	infect	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
1	CD	1	1	1	N	O
patient	NN	patient	patient	patient	N	O
(	(	(	(	(	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
no	DT	no	no	no	N	B-Negation
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

Dermatologic	NNP	dermatologic	dermatologic	dermatolog	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Epidermal	NNP	epidermal	epidermal	epiderm	N	B-AdverseReaction
and	CC	and	and	and	N	O
dermal	JJ	dermal	dermal	dermal	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
(	(	(	(	(	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
dermatitis	NN	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
,	,	,	,	,	N	O
eczema	NN	eczema	eczema	eczema	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
rashes	NNS	rashes	rash	rash	N	B-AdverseReaction
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
4	CD	4	4	4	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
3.3%	CD	3.3%	3.3%	3.3%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
5	CD	5	5	5	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
4.2%	CD	4.2%	4.2%	4.2%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

Osteonecrosis	NN	osteonecrosis	osteonecrosis	osteonecrosi	Y	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
Jaw	NNP	jaw	jaw	jaw	N	O
No	NNP	no	no	no	N	B-Negation
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
ONJ	NNP	onj	onj	onj	N	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

Pancreatitis	NNP	pancreatitis	pancreatitis	pancreat	Y	O
Pancreatitis	NNP	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
1	CD	1	1	1	N	O
patient	NN	patient	patient	patient	N	O
(	(	(	(	(	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
patient	NN	patient	patient	patient	N	O
(	(	(	(	(	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

New	NNP	new	new	new	N	O
Malignancies	NNP	malignancies	malignancy	malign	N	O
New	NNP	new	new	new	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
no	DT	no	no	no	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
3.3%	CD	3.3%	3.3%	3.3%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
prostate	NN	prostate	prostate	prostat	N	B-AdverseReaction
cancers	NNS	cancers	cancer	cancer	N	I-AdverseReaction
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
basal	NN	basal	basal	basal	N	B-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
carcinoma	NN	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

Treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
Bone	NNP	bone	bone	bone	N	O
Loss	NNP	loss	loss	loss	N	O
in	IN	in	in	in	N	O
Patients	NNP	patients	patient	patient	N	O
Receiving	NNP	receiving	receiving	receiv	N	O
Androgen	NNP	androgen	androgen	androgen	N	O
Deprivation	NNP	deprivation	deprivation	depriv	N	O
Therapy	NNP	therapy	therapy	therapi	N	O
for	IN	for	for	for	N	O
Prostate	NNP	prostate	prostate	prostat	N	O
Cancer	NNP	cancer	cancer	cancer	Y	O
or	CC	or	or	or	N	O
Adjuvant	NNP	adjuvant	adjuvant	adjuv	N	O
Aromatase	NNP	aromatase	aromatase	aromatas	N	O
Inhibitor	NNP	inhibitor	inhibitor	inhibitor	N	O
Therapy	NNP	therapy	therapy	therapi	N	O
for	IN	for	for	for	N	O
Breast	NNP	breast	breast	breast	N	O
Cancer	NNP	cancer	cancer	cancer	Y	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
bone	NN	bone	bone	bone	N	O
loss	NN	loss	loss	loss	N	O
in	IN	in	in	in	N	O
men	NNS	men	men	men	N	O
with	IN	with	with	with	N	O
nonmetastatic	JJ	nonmetastatic	nonmetastatic	nonmetastat	N	O
prostate	NN	prostate	prostate	prostat	N	O
cancer	NN	cancer	cancer	cancer	Y	O
receiving	VBG	receiving	receiving	receiv	N	O
androgen	JJ	androgen	androgen	androgen	N	O
deprivation	NN	deprivation	deprivation	depriv	N	O
therapy	NN	therapy	therapy	therapi	N	O
(	(	(	(	(	N	O
ADT	NNP	adt	adt	adt	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
assessed	VBN	assessed	assessed	assess	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
year	NN	year	year	year	N	O
,	,	,	,	,	N	O
randomized	VBN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
multinational	JJ	multinational	multinational	multin	N	O
study	NN	study	study	studi	N	O
of	IN	of	of	of	N	O
1468	CD	1468	1468	1468	N	O
men	NNS	men	men	men	N	O
aged	VBD	aged	aged	age	N	O
48	CD	48	48	48	N	O
to	TO	to	to	to	N	O
97	CD	97	97	97	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
725	CD	725	725	725	N	O
men	NNS	men	men	men	N	O
were	VBD	were	were	were	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
731	CD	731	731	731	N	O
men	NNS	men	men	men	N	O
were	VBD	were	were	were	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
administered	VBD	administered	administered	administ	N	O
once	RB	once	once	onc	N	O
every	DT	every	every	everi	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
60	CD	60	60	60	N	O
mg	NN	mg	mg	mg	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
men	NNS	men	men	men	N	O
were	VBD	were	were	were	N	O
instructed	VBN	instructed	instructed	instruct	N	O
to	TO	to	to	to	N	O
take	VB	take	take	take	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1000	CD	1000	1000	1000	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
calcium	NN	calcium	calcium	calcium	Y	O
and	CC	and	and	and	N	O
400	CD	400	400	400	N	O
IU	NNP	iu	iu	iu	N	O
of	IN	of	of	of	N	O
vitamin	NNP	vitamin	vitamin	vitamin	N	O
D	NNP	d	d	d	N	O
supplementation	NN	supplementation	supplementation	supplement	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
was	VBD	was	wa	wa	N	O
30.6%	CD	30.6%	30.6%	30.6%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
34.6%	CD	34.6%	34.6%	34.6%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
percentage	NN	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
withdrew	VBP	withdrew	withdrew	withdrew	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
study	NN	study	study	studi	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
was	VBD	was	wa	wa	N	O
6.1%	CD	6.1%	6.1%	6.1%	N	O
and	CC	and	and	and	N	O
7.0%	CD	7.0%	7.0%	7.0%	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
groups	NNS	groups	group	group	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
bone	NN	bone	bone	bone	N	O
loss	NN	loss	loss	loss	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
nonmetastatic	JJ	nonmetastatic	nonmetastatic	nonmetastat	N	O
breast	NN	breast	breast	breast	N	O
cancer	NN	cancer	cancer	cancer	Y	O
receiving	VBG	receiving	receiving	receiv	N	O
aromatase	NN	aromatase	aromatase	aromatas	N	O
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	O
(	(	(	(	(	N	O
AI	NNP	ai	ai	ai	N	O
)	)	)	)	)	N	O
therapy	NN	therapy	therapy	therapi	N	O
was	VBD	was	wa	wa	N	O
assessed	VBN	assessed	assessed	assess	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
year	NN	year	year	year	N	O
,	,	,	,	,	N	O
randomized	VBN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
multinational	JJ	multinational	multinational	multin	N	O
study	NN	study	study	studi	N	O
of	IN	of	of	of	N	O
252	CD	252	252	252	N	O
postmenopausal	JJ	postmenopausal	postmenopausal	postmenopaus	N	O
women	NNS	women	woman	women	N	O
aged	VBD	aged	aged	age	N	O
35	CD	35	35	35	N	O
to	TO	to	to	to	N	O
84	CD	84	84	84	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
120	CD	120	120	120	N	O
women	NNS	women	woman	women	N	O
were	VBD	were	were	were	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
129	CD	129	129	129	N	O
women	NNS	women	woman	women	N	O
were	VBD	were	were	were	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
administered	VBD	administered	administered	administ	N	O
once	RB	once	once	onc	N	O
every	DT	every	every	everi	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
60	CD	60	60	60	N	O
mg	NN	mg	mg	mg	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
women	NNS	women	woman	women	N	O
were	VBD	were	were	were	N	O
instructed	VBN	instructed	instructed	instruct	N	O
to	TO	to	to	to	N	O
take	VB	take	take	take	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1000	CD	1000	1000	1000	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
calcium	NN	calcium	calcium	calcium	Y	O
and	CC	and	and	and	N	O
400	CD	400	400	400	N	O
IU	NNP	iu	iu	iu	N	O
of	IN	of	of	of	N	O
vitamin	NNP	vitamin	vitamin	vitamin	N	O
D	NNP	d	d	d	N	O
supplementation	NN	supplementation	supplementation	supplement	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
was	VBD	was	wa	wa	N	O
9.2%	CD	9.2%	9.2%	9.2%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
14.7%	CD	14.7%	14.7%	14.7%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
percentage	NN	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
withdrew	VBP	withdrew	withdrew	withdrew	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
study	NN	study	study	studi	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
was	VBD	was	wa	wa	N	O
4.2%	CD	4.2%	4.2%	4.2%	N	O
and	CC	and	and	and	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
groups	NNS	groups	group	group	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
ADT	NNP	adt	adt	adt	N	O
for	IN	for	for	for	N	O
prostate	NN	prostate	prostate	prostat	N	O
cancer	NN	cancer	cancer	cancer	Y	O
or	CC	or	or	or	N	O
adjuvant	JJ	adjuvant	adjuvant	adjuv	N	O
AI	NNP	ai	ai	ai	N	O
therapy	NN	therapy	therapy	therapi	N	O
for	IN	for	for	for	N	O
breast	NN	breast	breast	breast	N	O
cancer	NN	cancer	cancer	cancer	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
(	(	(	(	(	N	O
13.0%	CD	13.0%	13.0%	13.0%	N	O
placebo	NN	placebo	placebo	placebo	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

14.3%	CD	14.3%	14.3%	14.3%	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
(	(	(	(	(	N	O
10.5%	CD	10.5%	10.5%	10.5%	N	O
placebo	NN	placebo	placebo	placebo	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

11.5%	CD	11.5%	11.5%	11.5%	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
(	(	(	(	(	N	O
7.7%	CD	7.7%	7.7%	7.7%	N	O
placebo	NN	placebo	placebo	placebo	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

9.9%	CD	9.9%	9.9%	9.9%	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
(	(	(	(	(	N	O
3.8%	CD	3.8%	3.8%	3.8%	N	O
placebo	NN	placebo	placebo	placebo	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

6.0%	CD	6.0%	6.0%	6.0%	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Additionally	RB	additionally	additionally	addit	N	O
in	IN	in	in	in	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
men	NNS	men	men	men	N	O
with	IN	with	with	with	N	O
nonmetastatic	JJ	nonmetastatic	nonmetastatic	nonmetastat	N	O
prostate	NN	prostate	prostate	prostat	N	O
cancer	NN	cancer	cancer	cancer	Y	O
receiving	VBG	receiving	receiving	receiv	N	O
ADT	NNP	adt	adt	adt	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
greater	JJR	greater	greater	greater	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
cataracts	NNS	cataracts	cataract	cataract	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
(	(	(	(	(	N	O
1.2%	CD	1.2%	1.2%	1.2%	N	O
placebo	NN	placebo	placebo	placebo	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

4.7%	CD	4.7%	4.7%	4.7%	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Hypocalcemia	NNP	hypocalcemia	hypocalcemia	hypocalcemia	Y	B-AdverseReaction
(	(	(	(	(	N	O
serum	JJ	serum	serum	serum	N	O
calcium	NN	calcium	calcium	calcium	Y	O
8.4	CD	8.4	8.4	8.4	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
only	RB	only	only	onli	N	O
in	IN	in	in	in	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
2.4%	CD	2.4%	2.4%	2.4%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

0%	CD	0%	0%	0%	N	O
)	)	)	)	)	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
month	NN	month	month	month	N	O
1	CD	1	1	1	N	O
visit	NN	visit	visit	visit	N	O
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
Prolia	NNS	prolia	prolia	prolia	N	O
:	:	:	:	:	N	O

Drug	NNP	drug	drug	drug	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
:	:	:	:	:	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
urticaria	NN	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
facial	JJ	facial	facial	facial	N	B-AdverseReaction
swelling	NN	swelling	swelling	swell	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction

Hypocalcemia	NN	hypocalcemia	hypocalcemia	hypocalcemia	Y	B-AdverseReaction
:	:	:	:	:	N	O
severe	JJ	severe	severe	sever	N	B-Severity
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	B-AdverseReaction
hypocalcemia	NN	hypocalcemia	hypocalcemia	hypocalcemia	Y	I-AdverseReaction

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
severe	JJ	severe	severe	sever	N	B-Severity
cases	NNS	cases	case	case	N	O

Parathyroid	NNP	parathyroid	parathyroid	parathyroid	N	O
Hormone	NNP	hormone	hormone	hormon	N	O
(	(	(	(	(	N	O
PTH	NNP	pth	pth	pth	Y	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O
Marked	VBN	marked	marked	mark	N	B-Severity
elevation	NN	elevation	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	NN	serum	serum	serum	N	I-AdverseReaction
PTH	NNP	pth	pth	pth	Y	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
(	(	(	(	(	N	O
creatinine	JJ	creatinine	creatinine	creatinin	Y	O
clearance	NN	clearance	clearance	clearanc	N	O
30	CD	30	30	30	N	O
mL	NN	ml	ml	ml	N	O
min	NN	min	min	min	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
receiving	VBG	receiving	receiving	receiv	N	O
dialysis	NN	dialysis	dialysis	dialysi	Y	O
.	.	.	.	.	N	O

6.3	CD	6.3	6.3	6.3	N	O
Immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O

Denosumab	NNP	denosumab	denosumab	denosumab	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
human	JJ	human	human	human	N	O
monoclonal	JJ	monoclonal	monoclonal	monoclon	N	O
antibody	NN	antibody	antibody	antibodi	N	O
.	.	.	.	.	N	O

As	IN	as	a	as	N	O
with	IN	with	with	with	N	O
all	DT	all	all	all	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
proteins	NNS	proteins	protein	protein	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
potential	JJ	potential	potential	potenti	N	O
for	IN	for	for	for	N	O
immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O
.	.	.	.	.	N	O

Using	VBG	using	using	use	N	O
an	DT	an	an	an	N	O
electrochemiluminescent	NN	electrochemiluminescent	electrochemiluminescent	electrochemiluminesc	N	O
bridging	VBG	bridging	bridging	bridg	N	O
immunoassay	NN	immunoassay	immunoassay	immunoassay	N	O
,	,	,	,	,	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
(	(	(	(	(	N	O
55	CD	55	55	55	N	O
out	IN	out	out	out	N	O
of	IN	of	of	of	N	O
8113	CD	8113	8113	8113	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
for	IN	for	for	for	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
5	CD	5	5	5	N	O
years	NNS	years	year	year	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
binding	VBG	binding	binding	bind	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
pre	SYM	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	NN	existing	existing	exist	N	O
,	,	,	,	,	N	O
transient	NN	transient	transient	transient	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
developing	VBG	developing	developing	develop	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

None	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
was	VBD	was	wa	wa	N	O
assessed	VBN	assessed	assessed	assess	N	O
using	VBG	using	using	use	N	O
a	DT	a	a	a	N	O
chemiluminescent	NN	chemiluminescent	chemiluminescent	chemiluminesc	N	O
cell	NN	cell	cell	cell	N	O
-	:	-	-	-	N	O
based	VBN	based	based	base	N	O
in	IN	in	in	in	N	O
vitro	JJ	vitro	vitro	vitro	N	O
biological	JJ	biological	biological	biolog	N	O
assay	NN	assay	assay	assay	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	B-Negation
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
altered	JJ	altered	altered	alter	N	O
pharmacokinetic	JJ	pharmacokinetic	pharmacokinetic	pharmacokinet	N	O
profile	NN	profile	profile	profil	N	O
,	,	,	,	,	N	O
toxicity	NN	toxicity	toxicity	toxic	N	B-AdverseReaction
profile	NN	profile	profile	profil	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
clinical	JJ	clinical	clinical	clinic	N	O
response	NN	response	response	respons	N	O
was	VBD	was	wa	wa	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
binding	VBG	binding	binding	bind	N	O
antibody	NN	antibody	antibody	antibodi	N	O
development	NN	development	development	develop	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
formation	NN	formation	formation	format	N	O
is	VBZ	is	is	is	N	O
highly	RB	highly	highly	highli	N	O
dependent	JJ	dependent	dependent	depend	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
and	CC	and	and	and	N	O
specificity	NN	specificity	specificity	specif	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
assay	NN	assay	assay	assay	N	O
.	.	.	.	.	N	O

Additionally	RB	additionally	additionally	addit	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
observed	JJ	observed	observed	observ	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
positive	JJ	positive	positive	posit	N	O
antibody	NN	antibody	antibody	antibodi	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibody	NN	antibody	antibody	antibodi	N	O
)	)	)	)	)	N	O
test	NN	test	test	test	N	O
result	NN	result	result	result	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
influenced	VBN	influenced	influenced	influenc	N	O
by	IN	by	by	by	N	O
several	JJ	several	several	sever	N	O
factors	NNS	factors	factor	factor	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
assay	JJ	assay	assay	assay	N	O
methodology	NN	methodology	methodology	methodolog	N	O
,	,	,	,	,	N	O
sample	NN	sample	sample	sampl	N	O
handling	NN	handling	handling	handl	N	O
,	,	,	,	,	N	O
timing	NN	timing	timing	time	N	O
of	IN	of	of	of	N	O
sample	JJ	sample	sample	sampl	N	O
collection	NN	collection	collection	collect	N	O
,	,	,	,	,	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
underlying	JJ	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
these	DT	these	these	these	N	O
reasons	NNS	reasons	reason	reason	N	O
,	,	,	,	,	N	O
comparison	NN	comparison	comparison	comparison	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
denosumab	VB	denosumab	denosumab	denosumab	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
other	JJ	other	other	other	N	O
products	NNS	products	product	product	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
misleading	VBG	misleading	misleading	mislead	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Same	NNP	same	same	same	N	O
Active	NNP	active	active	activ	N	O
Ingredient	NNP	ingredient	ingredient	ingredi	N	O
:	:	:	:	:	N	O
Patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
receive	VB	receive	receive	receiv	N	O
XGEVA	NNP	xgeva	xgeva	xgeva	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
including	VBG	including	including	includ	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
may	MD	may	may	may	N	O
occur	VB	occur	occur	occur	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
permanently	RB	permanently	permanently	perman	N	O
if	IN	if	if	if	N	O
a	DT	a	a	a	N	O
clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
reaction	NN	reaction	reaction	reaction	N	O
occurs	VBZ	occurs	occurs	occur	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Hypocalcemia	NN	hypocalcemia	hypocalcemia	hypocalcemia	Y	B-AdverseReaction
:	:	:	:	:	N	O
Must	NN	must	must	must	N	O
be	VB	be	be	be	N	O
corrected	VBN	corrected	corrected	correct	N	O
before	IN	before	before	befor	N	O
initiating	VBG	initiating	initiating	initi	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
.	.	.	.	.	N	O

May	NNP	may	may	may	N	O
worsen	NN	worsen	worsen	worsen	N	O
,	,	,	,	,	N	O
especially	RB	especially	especially	especi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
.	.	.	.	.	N	O

Adequately	RB	adequately	adequately	adequ	N	O
supplement	JJ	supplement	supplement	supplement	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
calcium	NN	calcium	calcium	calcium	Y	O
and	CC	and	and	and	N	O
vitamin	NN	vitamin	vitamin	vitamin	N	O
D	NNP	d	d	d	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Osteonecrosis	NN	osteonecrosis	osteonecrosis	osteonecrosi	Y	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
jaw	NN	jaw	jaw	jaw	N	I-AdverseReaction
:	:	:	:	:	N	O
Has	NNP	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Atypical	JJ	atypical	atypical	atyp	N	B-AdverseReaction
femoral	JJ	femoral	femoral	femor	N	I-AdverseReaction
fractures	NNS	fractures	fracture	fractur	N	I-AdverseReaction
:	:	:	:	:	N	O
Have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

Evaluate	JJ	evaluate	evaluate	evalu	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
thigh	JJ	thigh	thigh	thigh	N	O
or	CC	or	or	or	N	O
groin	JJ	groin	groin	groin	N	O
pain	NN	pain	pain	pain	Y	O
to	TO	to	to	to	N	O
rule	VB	rule	rule	rule	N	O
out	RP	out	out	out	N	O
a	DT	a	a	a	N	O
femoral	JJ	femoral	femoral	femor	N	O
fracture	NN	fracture	fracture	fractur	Y	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
including	VBG	including	including	includ	N	O
skin	JJ	skin	skin	skin	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
:	:	:	:	:	N	O
May	NNP	may	may	may	N	O
occur	VB	occur	occur	occur	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
those	DT	those	those	those	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
.	.	.	.	.	N	O

Advise	NN	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
seek	VB	seek	seek	seek	N	O
prompt	NN	prompt	prompt	prompt	N	O
medical	JJ	medical	medical	medic	N	O
attention	NN	attention	attention	attent	N	O
if	IN	if	if	if	N	O
they	PRP	they	they	they	N	O
develop	VBP	develop	develop	develop	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
cellulitis	NN	cellulitis	cellulitis	cellul	Y	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Dermatologic	JJ	dermatologic	dermatologic	dermatolog	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
:	:	:	:	:	N	O
Dermatitis	NN	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
,	,	,	,	,	N	O
rashes	NNS	rashes	rash	rash	N	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
eczema	NNS	eczema	eczema	eczema	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
discontinuing	VBG	discontinuing	discontinuing	discontinu	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
if	IN	if	if	if	N	O
severe	JJ	severe	severe	sever	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
develop	VBP	develop	develop	develop	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

Severe	NNP	severe	severe	sever	N	B-Severity
Bone	NNP	bone	bone	bone	N	B-AdverseReaction
,	,	,	,	,	N	O
Joint	NNP	joint	joint	joint	N	B-AdverseReaction
,	,	,	,	,	N	O
Muscle	NNP	muscle	muscle	muscl	N	B-AdverseReaction
Pain	NNP	pain	pain	pain	Y	I-AdverseReaction
may	MD	may	may	may	N	O
occur	VB	occur	occur	occur	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
use	NN	use	use	use	N	O
if	IN	if	if	if	N	O
severe	JJ	severe	severe	sever	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
develop	VBP	develop	develop	develop	N	O
(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O

Suppression	NN	suppression	suppression	suppress	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
bone	NN	bone	bone	bone	N	I-AdverseReaction
turnover	NN	turnover	turnover	turnov	N	I-AdverseReaction
:	:	:	:	:	N	O
Significant	JJ	significant	significant	signific	N	O
suppression	NN	suppression	suppression	suppress	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
demonstrated	VBN	demonstrated	demonstrated	demonstr	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
consequences	NNS	consequences	consequence	consequ	N	O
of	IN	of	of	of	N	O
bone	NN	bone	bone	bone	N	O
oversuppression	NN	oversuppression	oversuppression	oversuppress	N	O
(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Drug	NN	drug	drug	drug	N	O

Products	NNS	products	product	product	N	O
with	IN	with	with	with	N	O
Same	NNP	same	same	same	N	O
Active	NNP	active	active	activ	N	O
Ingredient	NNP	ingredient	ingredient	ingredi	N	O

Prolia	NNP	prolia	prolia	prolia	N	O
contains	VBZ	contains	contains	contain	N	O
the	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
active	JJ	active	active	activ	N	O
ingredient	NN	ingredient	ingredient	ingredi	N	O
(	(	(	(	(	N	O
denosumab	NN	denosumab	denosumab	denosumab	N	O
)	)	)	)	)	N	O
found	VBD	found	found	found	N	O
in	IN	in	in	in	N	O
Xgeva	NNP	xgeva	xgeva	xgeva	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
receive	VB	receive	receive	receiv	N	O
Xgeva	NN	xgeva	xgeva	xgeva	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O

Clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
including	VBG	including	including	includ	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
.	.	.	.	.	N	O

Symptoms	NNS	symptoms	symptom	symptom	N	O
have	VBP	have	have	have	N	O
included	VBN	included	included	includ	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
throat	NN	throat	throat	throat	N	B-AdverseReaction
tightness	NN	tightness	tightness	tight	N	I-AdverseReaction
,	,	,	,	,	N	O
facial	JJ	facial	facial	facial	N	B-AdverseReaction
and	CC	and	and	and	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
airway	NN	airway	airway	airway	N	I-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
urticaria	NNS	urticaria	urticaria	urticaria	Y	B-AdverseReaction
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
an	DT	an	an	an	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
allergic	JJ	allergic	allergic	allerg	N	O
reaction	NN	reaction	reaction	reaction	N	O
occurs	VBZ	occurs	occurs	occur	N	O
,	,	,	,	,	N	O
initiate	VB	initiate	initiate	initi	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
further	JJR	further	further	further	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4.3	CD	4.3	4.3	4.3	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.2	CD	6.2	6.2	6.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Hypocalcemia	NNP	hypocalcemia	hypocalcemia	hypocalcemia	Y	O
and	CC	and	and	and	N	O
Mineral	NNP	mineral	mineral	miner	N	O
Metabolism	NNP	metabolism	metabolism	metabol	N	O

Hypocalcemia	NN	hypocalcemia	hypocalcemia	hypocalcemia	Y	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
exacerbated	VBN	exacerbated	exacerbated	exacerb	N	I-AdverseReaction
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
.	.	.	.	.	N	O

Pre	NNP	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
hypocalcemia	NN	hypocalcemia	hypocalcemia	hypocalcemia	Y	O
must	MD	must	must	must	N	O
be	VB	be	be	be	N	O
corrected	VBN	corrected	corrected	correct	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
predisposed	VBN	predisposed	predisposed	predispos	N	O
to	TO	to	to	to	N	O
hypocalcemia	VB	hypocalcemia	hypocalcemia	hypocalcemia	Y	O
and	CC	and	and	and	N	O
disturbances	NNS	disturbances	disturbance	disturb	N	O
of	IN	of	of	of	N	O
mineral	JJ	mineral	mineral	miner	N	O
metabolism	NN	metabolism	metabolism	metabol	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O

history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
hypoparathyroidism	NN	hypoparathyroidism	hypoparathyroidism	hypoparathyroid	Y	O
,	,	,	,	,	N	O
thyroid	NN	thyroid	thyroid	thyroid	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
,	,	,	,	,	N	O
parathyroid	NN	parathyroid	parathyroid	parathyroid	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
,	,	,	,	,	N	O
malabsorption	NN	malabsorption	malabsorption	malabsorpt	Y	O
syndromes	NNS	syndromes	syndrome	syndrom	N	O
,	,	,	,	,	N	O
excision	NN	excision	excision	excis	N	O
of	IN	of	of	of	N	O
small	JJ	small	small	small	N	O
intestine	NN	intestine	intestine	intestin	N	O
,	,	,	,	,	N	O
severe	JJ	severe	severe	sever	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
[	NNP	[	[	[	N	O
creatinine	NN	creatinine	creatinine	creatinin	Y	O
clearance	NN	clearance	clearance	clearanc	N	O
30	CD	30	30	30	N	O
mL	NN	ml	ml	ml	N	O
min	NN	min	min	min	N	O
]	NN	]	]	]	N	O
or	CC	or	or	or	N	O
receiving	VBG	receiving	receiving	receiv	N	O
dialysis	NN	dialysis	dialysis	dialysi	Y	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
clinical	JJ	clinical	clinical	clinic	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
calcium	NN	calcium	calcium	calcium	Y	O
and	CC	and	and	and	N	O
mineral	NN	mineral	mineral	miner	N	O
levels	NNS	levels	level	level	N	O
(	(	(	(	(	N	O
phosphorus	NN	phosphorus	phosphorus	phosphoru	Y	O
and	CC	and	and	and	N	O
magnesium	NN	magnesium	magnesium	magnesium	Y	O
)	)	)	)	)	N	O
is	VBZ	is	is	is	N	O
highly	RB	highly	highly	highli	N	O
recommended	VBN	recommended	recommended	recommend	N	O
within	IN	within	within	within	N	O
14	CD	14	14	14	N	O
days	NNS	days	day	day	N	O
of	IN	of	of	of	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
injection	NN	injection	injection	inject	Y	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
some	DT	some	some	some	N	O
postmarketing	NN	postmarketing	postmarketing	postmarket	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
hypocalcemia	NN	hypocalcemia	hypocalcemia	hypocalcemia	Y	B-AdverseReaction
persisted	VBD	persisted	persisted	persist	N	O
for	IN	for	for	for	N	O
weeks	NNS	weeks	week	week	N	O
or	CC	or	or	or	N	O
months	NNS	months	month	month	N	O
and	CC	and	and	and	N	O
required	VBN	required	required	requir	N	O
frequent	JJ	frequent	frequent	frequent	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
and	CC	and	and	and	N	O
intravenous	JJ	intravenous	intravenous	intraven	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
oral	JJ	oral	oral	oral	N	O
calcium	NN	calcium	calcium	calcium	Y	O
replacement	NN	replacement	replacement	replac	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
or	CC	or	or	or	N	O
without	IN	without	without	without	N	O
vitamin	JJ	vitamin	vitamin	vitamin	N	O
D.	NNP	d.	d.	d.	N	O

Hypocalcemia	NNP	hypocalcemia	hypocalcemia	hypocalcemia	Y	B-AdverseReaction
following	VBG	following	following	follow	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
administration	NN	administration	administration	administr	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
significant	JJ	significant	significant	signific	N	O
risk	NN	risk	risk	risk	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
[	NNP	[	[	[	N	O
creatinine	NN	creatinine	creatinine	creatinin	Y	O
clearance	NN	clearance	clearance	clearanc	N	O
30	CD	30	30	30	N	O
mL	NN	ml	ml	ml	N	O
min	NN	min	min	min	N	O
]	NN	]	]	]	N	O
or	CC	or	or	or	N	O
receiving	VBG	receiving	receiving	receiv	N	O
dialysis	NN	dialysis	dialysis	dialysi	Y	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
may	MD	may	may	may	N	B-Factor
also	RB	also	also	also	N	O
develop	VB	develop	develop	develop	N	O
marked	JJ	marked	marked	mark	N	B-Severity
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
serum	NN	serum	serum	serum	N	I-AdverseReaction
parathyroid	NN	parathyroid	parathyroid	parathyroid	N	I-AdverseReaction
hormone	NN	hormone	hormone	hormon	N	I-AdverseReaction
(	(	(	(	(	N	O
PTH	NNP	pth	pth	pth	Y	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Instruct	NNP	instruct	instruct	instruct	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
those	DT	those	those	those	N	O
receiving	VBG	receiving	receiving	receiv	N	O
dialysis	NN	dialysis	dialysis	dialysi	Y	O
,	,	,	,	,	N	O
about	IN	about	about	about	N	O
the	DT	the	the	the	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
hypocalcemia	NN	hypocalcemia	hypocalcemia	hypocalcemia	Y	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
importance	NN	importance	importance	import	N	O
of	IN	of	of	of	N	O
maintaining	VBG	maintaining	maintaining	maintain	N	O
calcium	NN	calcium	calcium	calcium	Y	O
levels	NNS	levels	level	level	N	O
with	IN	with	with	with	N	O
adequate	JJ	adequate	adequate	adequ	N	O
calcium	NN	calcium	calcium	calcium	Y	O
and	CC	and	and	and	N	O
vitamin	NN	vitamin	vitamin	vitamin	N	O
D	NNP	d	d	d	N	O
supplementation	NN	supplementation	supplementation	supplement	N	O
.	.	.	.	.	N	O

Adequately	RB	adequately	adequately	adequ	N	O
supplement	JJ	supplement	supplement	supplement	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
calcium	NN	calcium	calcium	calcium	Y	O
and	CC	and	and	and	N	O
vitamin	NN	vitamin	vitamin	vitamin	N	O
D	NNP	d	d	d	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4.1	CD	4.1	4.1	4.1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Patient	NNP	patient	patient	patient	N	O
Counseling	NNP	counseling	counseling	counsel	N	O
Information	NNP	information	information	inform	N	O
(	(	(	(	(	N	O
17.3	CD	17.3	17.3	17.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Osteonecrosis	NN	osteonecrosis	osteonecrosis	osteonecrosi	Y	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
Jaw	NNP	jaw	jaw	jaw	N	O

Osteonecrosis	NN	osteonecrosis	osteonecrosis	osteonecrosi	Y	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
jaw	NN	jaw	jaw	jaw	N	O
(	(	(	(	(	N	O
ONJ	NNP	onj	onj	onj	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
can	MD	can	can	can	N	O
occur	VB	occur	occur	occur	N	O
spontaneously	RB	spontaneously	spontaneously	spontan	N	O
,	,	,	,	,	N	O
is	VBZ	is	is	is	N	O
generally	RB	generally	generally	gener	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
tooth	DT	tooth	tooth	tooth	N	O
extraction	NN	extraction	extraction	extract	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
local	JJ	local	local	local	N	O
infection	NN	infection	infection	infect	Y	O
with	IN	with	with	with	N	O
delayed	JJ	delayed	delayed	delay	N	O
healing	NN	healing	healing	heal	N	O
.	.	.	.	.	N	O

ONJ	NNP	onj	onj	onj	N	B-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
denosumab	JJ	denosumab	denosumab	denosumab	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
routine	JJ	routine	routine	routin	N	O
oral	JJ	oral	oral	oral	N	O
exam	NN	exam	exam	exam	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
performed	VBN	performed	performed	perform	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
prescriber	NN	prescriber	prescriber	prescrib	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
dental	JJ	dental	dental	dental	N	O
examination	NN	examination	examination	examin	N	O
with	IN	with	with	with	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
preventive	JJ	preventive	preventive	prevent	N	O
dentistry	NN	dentistry	dentistry	dentistri	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
ONJ	NNP	onj	onj	onj	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
invasive	JJ	invasive	invasive	invas	N	O
dental	NN	dental	dental	dental	N	O
procedures	NNS	procedures	procedure	procedur	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O

tooth	DT	tooth	tooth	tooth	N	O
extraction	NN	extraction	extraction	extract	N	O
,	,	,	,	,	N	O
dental	JJ	dental	dental	dental	N	O
implants	NNS	implants	implant	implant	N	O
,	,	,	,	,	N	O
oral	JJ	oral	oral	oral	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
cancer	NN	cancer	cancer	cancer	Y	O
,	,	,	,	,	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
therapies	NNS	therapies	therapy	therapi	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O

chemotherapy	NN	chemotherapy	chemotherapy	chemotherapi	Y	O
,	,	,	,	,	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
,	,	,	,	,	N	O
angiogenesis	NN	angiogenesis	angiogenesis	angiogenesi	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
poor	JJ	poor	poor	poor	N	O
oral	JJ	oral	oral	oral	N	O
hygiene	NN	hygiene	hygiene	hygien	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
co	SYM	co	co	co	N	O
-	:	-	-	-	N	O
morbid	NN	morbid	morbid	morbid	N	O
disorders	NNS	disorders	disorder	disord	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O

periodontal	NN	periodontal	periodontal	periodont	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
pre	JJ	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
dental	JJ	dental	dental	dental	N	O
disease	NN	disease	disease	diseas	N	O
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	O
,	,	,	,	,	N	O
coagulopathy	NN	coagulopathy	coagulopathy	coagulopathi	Y	O
,	,	,	,	,	N	O
infection	NN	infection	infection	infect	Y	O
,	,	,	,	,	N	O
ill	VB	ill	ill	ill	N	O
-	:	-	-	-	N	O
fitting	NN	fitting	fitting	fit	N	O
dentures	NNS	dentures	denture	dentur	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Good	JJ	good	good	good	N	O
oral	JJ	oral	oral	oral	N	O
hygiene	NN	hygiene	hygiene	hygien	N	O
practices	NNS	practices	practice	practic	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
maintained	VBN	maintained	maintained	maintain	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
.	.	.	.	.	N	O

Concomitant	JJ	concomitant	concomitant	concomit	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
drugs	NNS	drugs	drug	drug	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
ONJ	NNP	onj	onj	onj	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
developing	VBG	developing	developing	develop	N	O
ONJ	NNP	onj	onj	onj	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
requiring	VBG	requiring	requiring	requir	N	O
invasive	JJ	invasive	invasive	invas	N	O
dental	NN	dental	dental	dental	N	O
procedures	NNS	procedures	procedure	procedur	N	O
,	,	,	,	,	N	O
clinical	JJ	clinical	clinical	clinic	N	O
judgment	NN	judgment	judgment	judgment	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
treating	NN	treating	treating	treat	N	O
physician	NN	physician	physician	physician	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
oral	JJ	oral	oral	oral	N	O
surgeon	NN	surgeon	surgeon	surgeon	N	O
should	MD	should	should	should	N	O
guide	VB	guide	guide	guid	N	O
the	DT	the	the	the	N	O
management	NN	management	management	manag	N	O
plan	NN	plan	plan	plan	N	O
of	IN	of	of	of	N	O
each	DT	each	each	each	N	O
patient	NN	patient	patient	patient	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
individual	JJ	individual	individual	individu	N	O
benefit	NN	benefit	benefit	benefit	N	O
-	:	-	-	-	N	O
risk	NN	risk	risk	risk	N	O
assessment	NN	assessment	assessment	assess	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
suspected	VBN	suspected	suspected	suspect	N	O
of	IN	of	of	of	N	O
having	VBG	having	having	have	N	O
or	CC	or	or	or	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
ONJ	NNP	onj	onj	onj	N	O
while	IN	while	while	while	N	O
on	IN	on	on	on	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
should	MD	should	should	should	N	O
receive	VB	receive	receive	receiv	N	O
care	NN	care	care	care	N	O
by	IN	by	by	by	N	O
a	DT	a	a	a	N	O
dentist	NN	dentist	dentist	dentist	N	O
or	CC	or	or	or	N	O
an	DT	an	an	an	N	O
oral	JJ	oral	oral	oral	N	O
surgeon	NN	surgeon	surgeon	surgeon	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
extensive	JJ	extensive	extensive	extens	N	O
dental	NN	dental	dental	dental	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
to	TO	to	to	to	N	O
treat	VB	treat	treat	treat	N	O
ONJ	NNP	onj	onj	onj	N	O
may	MD	may	may	may	N	O
exacerbate	VB	exacerbate	exacerbate	exacerb	N	O
the	DT	the	the	the	N	O
condition	NN	condition	condition	condit	N	O
.	.	.	.	.	N	O

Discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
therapy	NN	therapy	therapy	therapi	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
individual	JJ	individual	individual	individu	N	O
benefit	NN	benefit	benefit	benefit	N	O
-	:	-	-	-	N	O
risk	NN	risk	risk	risk	N	O
assessment	NN	assessment	assessment	assess	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Atypical	NNP	atypical	atypical	atyp	N	O
Subtrochanteric	NNP	subtrochanteric	subtrochanteric	subtrochanter	N	O
and	CC	and	and	and	N	O
Diaphyseal	NNP	diaphyseal	diaphyseal	diaphys	N	O
Femoral	NNP	femoral	femoral	femor	N	B-AdverseReaction
Fractures	NNP	fractures	fracture	fractur	N	O

Atypical	NNP	atypical	atypical	atyp	N	I-AdverseReaction
low	JJ	low	low	low	N	O
-	:	-	-	-	N	O
energy	NN	energy	energy	energi	N	O
or	CC	or	or	or	N	O
low	JJ	low	low	low	N	O
trauma	NN	trauma	trauma	trauma	Y	O
fractures	NNS	fractures	fracture	fractur	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
shaft	NN	shaft	shaft	shaft	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
fractures	NNS	fractures	fracture	fractur	N	B-AdverseReaction
can	MD	can	can	can	N	O
occur	VB	occur	occur	occur	N	O
anywhere	RB	anywhere	anywhere	anywher	N	O
in	IN	in	in	in	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
femoral	JJ	femoral	femoral	femor	N	I-AdverseReaction
shaft	NN	shaft	shaft	shaft	N	I-AdverseReaction
from	IN	from	from	from	N	O
just	RB	just	just	just	N	O
below	IN	below	below	below	N	O
the	DT	the	the	the	N	O
lesser	JJR	lesser	lesser	lesser	N	O
trochanter	NN	trochanter	trochanter	trochant	N	O
to	TO	to	to	to	N	O
above	VB	above	above	abov	N	O
the	DT	the	the	the	N	O
supracondylar	JJ	supracondylar	supracondylar	supracondylar	N	O
flare	NN	flare	flare	flare	N	O
and	CC	and	and	and	N	O
are	VBP	are	are	are	N	O
transverse	JJ	transverse	transverse	transvers	N	O
or	CC	or	or	or	N	O
short	JJ	short	short	short	N	O
oblique	NN	oblique	oblique	obliqu	N	O
in	IN	in	in	in	N	O
orientation	NN	orientation	orientation	orient	N	O
without	IN	without	without	without	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
comminution	NN	comminution	comminution	comminut	N	O
.	.	.	.	.	N	O

Causality	NNP	causality	causality	causal	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
established	VBN	established	established	establish	N	O
as	IN	as	a	as	N	O
these	DT	these	these	these	N	O
fractures	NNS	fractures	fracture	fractur	N	O
also	RB	also	also	also	N	O
occur	VBP	occur	occur	occur	N	O
in	IN	in	in	in	N	O
osteoporotic	JJ	osteoporotic	osteoporotic	osteoporot	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
resorptive	JJ	resorptive	resorptive	resorpt	N	O
agents	NNS	agents	agent	agent	N	O
.	.	.	.	.	N	O

Atypical	JJ	atypical	atypical	atyp	N	B-AdverseReaction
femoral	JJ	femoral	femoral	femor	N	I-AdverseReaction
fractures	NNS	fractures	fracture	fractur	N	I-AdverseReaction
most	RBS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
occur	VBP	occur	occur	occur	N	O
with	IN	with	with	with	N	O
minimal	JJ	minimal	minimal	minim	N	O
or	CC	or	or	or	N	O
no	DT	no	no	no	N	O
trauma	NN	trauma	trauma	trauma	Y	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
affected	JJ	affected	affected	affect	N	O
area	NN	area	area	area	N	O
.	.	.	.	.	N	O

They	PRP	they	they	they	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
bilateral	JJ	bilateral	bilateral	bilater	N	O
and	CC	and	and	and	N	O
many	JJ	many	many	mani	N	O
patients	NNS	patients	patient	patient	N	O
report	VBP	report	report	report	N	O
prodromal	JJ	prodromal	prodromal	prodrom	N	O
pain	NN	pain	pain	pain	Y	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
affected	JJ	affected	affected	affect	N	O
area	NN	area	area	area	N	O
,	,	,	,	,	N	O
usually	RB	usually	usually	usual	N	O
presenting	VBG	presenting	presenting	present	N	O
as	IN	as	a	as	N	O
dull	NN	dull	dull	dull	N	O
,	,	,	,	,	N	O
aching	VBG	aching	aching	ach	N	O
thigh	JJ	thigh	thigh	thigh	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
weeks	NNS	weeks	week	week	N	O
to	TO	to	to	to	N	O
months	NNS	months	month	month	N	O
before	IN	before	before	befor	N	O
a	DT	a	a	a	N	O
complete	JJ	complete	complete	complet	N	O
fracture	NN	fracture	fracture	fractur	Y	O
occurs	VBZ	occurs	occurs	occur	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
reports	NNS	reports	report	report	N	O
note	VBP	note	note	note	N	O
that	IN	that	that	that	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
also	RB	also	also	also	N	O
receiving	VBG	receiving	receiving	receiv	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
glucocorticoids	NNS	glucocorticoids	glucocorticoid	glucocorticoid	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O

prednisone	NN	prednisone	prednisone	prednison	N	O
)	)	)	)	)	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
time	NN	time	time	time	N	O
of	IN	of	of	of	N	O
fracture	NN	fracture	fracture	fractur	Y	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
advised	VBN	advised	advised	advis	N	O
to	TO	to	to	to	N	O
report	VB	report	report	report	N	O
new	JJ	new	new	new	N	O
or	CC	or	or	or	N	O
unusual	JJ	unusual	unusual	unusu	N	O
thigh	NN	thigh	thigh	thigh	N	O
,	,	,	,	,	N	O
hip	NN	hip	hip	hip	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
groin	NN	groin	groin	groin	N	O
pain	NN	pain	pain	pain	Y	O
.	.	.	.	.	N	O

Any	DT	any	any	ani	N	O
patient	NN	patient	patient	patient	N	O
who	WP	who	who	who	N	O
presents	VBZ	presents	present	present	N	O
with	IN	with	with	with	N	O
thigh	JJ	thigh	thigh	thigh	N	O
or	CC	or	or	or	N	O
groin	JJ	groin	groin	groin	N	O
pain	NN	pain	pain	pain	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
suspected	VBN	suspected	suspected	suspect	N	O
of	IN	of	of	of	N	O
having	VBG	having	having	have	N	O
an	DT	an	an	an	N	O
atypical	JJ	atypical	atypical	atyp	N	O
fracture	NN	fracture	fracture	fractur	Y	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
to	TO	to	to	to	N	O
rule	VB	rule	rule	rule	N	O
out	RP	out	out	out	N	O
an	DT	an	an	an	N	O
incomplete	JJ	incomplete	incomplete	incomplet	N	O
femur	NN	femur	femur	femur	N	O
fracture	NN	fracture	fracture	fractur	Y	O
.	.	.	.	.	N	O

Patient	JJ	patient	patient	patient	N	O
presenting	VBG	presenting	presenting	present	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
atypical	JJ	atypical	atypical	atyp	N	O
femur	NN	femur	femur	femur	N	O
fracture	NN	fracture	fracture	fractur	Y	O
should	MD	should	should	should	N	O
also	RB	also	also	also	N	O
be	VB	be	be	be	N	O
assessed	VBN	assessed	assessed	assess	N	O
for	IN	for	for	for	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
and	CC	and	and	and	N	O
signs	NNS	signs	sign	sign	N	O
of	IN	of	of	of	N	O
fracture	NN	fracture	fracture	fractur	Y	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
contralateral	JJ	contralateral	contralateral	contralater	N	O
limb	NN	limb	limb	limb	N	O
.	.	.	.	.	N	O

Interruption	NN	interruption	interruption	interrupt	N	O
of	IN	of	of	of	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
therapy	NN	therapy	therapy	therapi	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
,	,	,	,	,	N	O
pending	VBG	pending	pending	pend	N	O
a	DT	a	a	a	N	O
risk	NN	risk	risk	risk	N	O
benefit	NN	benefit	benefit	benefit	N	O
assessment	NN	assessment	assessment	assess	N	O
,	,	,	,	,	N	O
on	IN	on	on	on	N	O
an	DT	an	an	an	N	O
individual	JJ	individual	individual	individu	N	O
basis	NN	basis	basis	basi	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Serious	JJ	serious	serious	seriou	N	O
Infections	NNS	infections	infection	infect	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
of	IN	of	of	of	N	O
over	IN	over	over	over	N	O
7800	CD	7800	7800	7800	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
postmenopausal	JJ	postmenopausal	postmenopausal	postmenopaus	N	O
osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
,	,	,	,	,	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
group	NN	group	group	group	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
skin	NN	skin	skin	skin	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
as	RB	as	a	as	N	O
well	RB	well	well	well	N	O
as	IN	as	a	as	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
abdomen	NNS	abdomen	abdomen	abdomen	N	I-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
ear	RB	ear	ear	ear	N	I-AdverseReaction
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
.	.	.	.	.	N	O

Endocarditis	NN	endocarditis	endocarditis	endocard	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
also	RB	also	also	also	N	O
reported	VBN	reported	reported	report	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
similar	JJ	similar	similar	similar	N	O
between	IN	between	between	between	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
groups	NNS	groups	group	group	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
similar	JJ	similar	similar	similar	N	O
between	IN	between	between	between	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
groups	NNS	groups	group	group	N	O
.	.	.	.	.	N	O

Advise	NN	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
seek	VB	seek	seek	seek	N	O
prompt	NN	prompt	prompt	prompt	N	O
medical	JJ	medical	medical	medic	N	O
attention	NN	attention	attention	attent	N	O
if	IN	if	if	if	N	O
they	PRP	they	they	they	N	O
develop	VBP	develop	develop	develop	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	O
infection	NN	infection	infection	infect	Y	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
cellulitis	NN	cellulitis	cellulitis	cellul	Y	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
immunosuppressant	JJ	immunosuppressant	immunosuppressant	immunosuppress	N	O
agents	NNS	agents	agent	agent	N	O
or	CC	or	or	or	N	O
with	IN	with	with	with	N	O
impaired	JJ	impaired	impaired	impair	N	O
immune	JJ	immune	immune	immun	N	O
systems	NNS	systems	system	system	N	O
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
the	DT	the	the	the	N	O
benefit	NN	benefit	benefit	benefit	N	O
-	:	-	-	-	N	O
risk	NN	risk	risk	risk	N	O
profile	NN	profile	profile	profil	N	O
in	IN	in	in	in	N	O
such	JJ	such	such	such	N	O
patients	NNS	patients	patient	patient	N	O
before	IN	before	before	befor	N	O
treating	VBG	treating	treating	treat	N	O
with	IN	with	with	with	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
serious	JJ	serious	serious	seriou	N	O
infections	NNS	infections	infection	infect	N	O
while	IN	while	while	while	N	O
on	IN	on	on	on	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
,	,	,	,	,	N	O
prescribers	NNS	prescribers	prescribers	prescrib	N	O
should	MD	should	should	should	N	O
assess	VB	assess	ass	assess	N	O
the	DT	the	the	the	N	O
need	NN	need	need	need	N	O
for	IN	for	for	for	N	O
continued	JJ	continued	continued	continu	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Dermatologic	NNP	dermatologic	dermatologic	dermatolog	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
large	JJ	large	large	larg	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
of	IN	of	of	of	N	O
over	IN	over	over	over	N	O
7800	CD	7800	7800	7800	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
postmenopausal	JJ	postmenopausal	postmenopausal	postmenopaus	N	O
osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
,	,	,	,	,	N	O
epidermal	JJ	epidermal	epidermal	epiderm	N	B-AdverseReaction
and	CC	and	and	and	N	O
dermal	JJ	dermal	dermal	dermal	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
dermatitis	NN	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
,	,	,	,	,	N	O
eczema	NN	eczema	eczema	eczema	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
rashes	NNS	rashes	rash	rash	N	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
significantly	RB	significantly	significantly	significantli	N	O
higher	JJR	higher	higher	higher	N	O
rate	NN	rate	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
group	NN	group	group	group	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

Most	JJS	most	most	most	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	O
specific	JJ	specific	specific	specif	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
injection	NN	injection	injection	inject	Y	O
site	NN	site	site	site	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
discontinuing	VBG	discontinuing	discontinuing	discontinu	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
if	IN	if	if	if	N	O
severe	JJ	severe	severe	sever	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
develop	VBP	develop	develop	develop	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
Pain	NN	pain	pain	pain	Y	O

In	IN	in	in	in	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
experience	NN	experience	experience	experi	N	O
,	,	,	,	,	N	O
severe	JJ	severe	severe	sever	N	B-Severity
and	CC	and	and	and	N	O
occasionally	RB	occasionally	occasionally	occasion	N	O
incapacitating	VBG	incapacitating	incapacitating	incapacit	N	B-Severity
bone	NN	bone	bone	bone	N	B-AdverseReaction
,	,	,	,	,	N	O
joint	NN	joint	joint	joint	N	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.2	CD	6.2	6.2	6.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
onset	VB	onset	onset	onset	N	O
of	IN	of	of	of	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
varied	VBN	varied	varied	vari	N	O
from	IN	from	from	from	N	O
one	CD	one	one	one	N	O
day	NN	day	day	day	N	O
to	TO	to	to	to	N	O
several	JJ	several	several	sever	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
starting	VBG	starting	starting	start	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
discontinuing	NN	discontinuing	discontinuing	discontinu	N	O
use	NN	use	use	use	N	O
if	IN	if	if	if	N	O
severe	JJ	severe	severe	sever	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
develop	VB	develop	develop	develop	N	O
[	JJ	[	[	[	N	O
see	VB	see	see	see	N	O
Patient	JJ	patient	patient	patient	N	O
Counseling	NNP	counseling	counseling	counsel	N	O
Information	NNP	information	information	inform	N	O
(	(	(	(	(	N	O
17.8	CD	17.8	17.8	17.8	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.9	CD	5.9	5.9	5.9	N	O
Suppression	NN	suppression	suppression	suppress	N	O
of	IN	of	of	of	N	O
Bone	NNP	bone	bone	bone	N	O
Turnover	NNP	turnover	turnover	turnov	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
postmenopausal	JJ	postmenopausal	postmenopausal	postmenopaus	N	O
osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
resulted	VBD	resulted	resulted	result	N	O
in	IN	in	in	in	N	O
significant	JJ	significant	significant	signific	N	O
suppression	NN	suppression	suppression	suppress	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
bone	NN	bone	bone	bone	N	I-AdverseReaction
remodeling	NN	remodeling	remodeling	remodel	N	I-AdverseReaction
as	IN	as	a	as	N	O
evidenced	VBN	evidenced	evidenced	evidenc	N	O
by	IN	by	by	by	N	O
markers	NNS	markers	marker	marker	N	O
of	IN	of	of	of	N	O
bone	NN	bone	bone	bone	N	O
turnover	NN	turnover	turnover	turnov	N	O
and	CC	and	and	and	N	O
bone	NN	bone	bone	bone	N	O
histomorphometry	NN	histomorphometry	histomorphometry	histomorphometri	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.2	CD	12.2	12.2	12.2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.1	CD	14.1	14.1	14.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
significance	NN	significance	significance	signific	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
findings	NNS	findings	finding	find	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
are	VBP	are	are	are	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
consequences	NNS	consequences	consequence	consequ	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
degree	NN	degree	degree	degre	N	O
of	IN	of	of	of	N	O
suppression	NN	suppression	suppression	suppress	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
bone	NN	bone	bone	bone	N	I-AdverseReaction
remodeling	VBG	remodeling	remodeling	remodel	N	I-AdverseReaction
observed	VBN	observed	observed	observ	N	O
with	IN	with	with	with	N	O
Prolia	NNP	prolia	prolia	prolia	N	O
may	MD	may	may	may	N	B-Factor
contribute	VB	contribute	contribute	contribut	N	O
to	TO	to	to	to	N	O
adverse	VB	adverse	adverse	advers	N	O
outcomes	NNS	outcomes	outcome	outcom	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
osteonecrosis	NN	osteonecrosis	osteonecrosis	osteonecrosi	Y	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
jaw	NN	jaw	jaw	jaw	N	I-AdverseReaction
,	,	,	,	,	N	O
atypical	JJ	atypical	atypical	atyp	N	B-AdverseReaction
fractures	NNS	fractures	fracture	fractur	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
delayed	JJ	delayed	delayed	delay	N	B-AdverseReaction
fracture	NN	fracture	fracture	fractur	Y	I-AdverseReaction
healing	NN	healing	healing	heal	N	I-AdverseReaction
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
these	DT	these	these	these	N	O
consequences	NNS	consequences	consequence	consequ	N	O
.	.	.	.	.	N	O

